Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
L. Ellis, B. German, J. N. Singh, D. L. Burkhart, A. Sheahan, H. Bergom, K. L. Morel, H. Beltran, J. Hwang, K. Lawrenson
This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.
bioRxiv · Jan 31, 2024 · PreprintCancer Biology
L. B. Jarvis, S. K. Howlett, D. Rainbow, V. Coppard, R. Ferreira, E. Needham, A. Prabhu, S. Alkwai, L. Ellis, Z. Georgieva, O. Suchanek, H. S. Mousa, K. T. Mahbubani, K. Saeb-Parsy, L. S. Wicker, J. L. Jones
The paper identifies CD8+FOXP3+ Tregs enriched in human tissues, expressing intracellular CD25 and tissue residency markers, and demonstrates their therapeutic potential and association with disease states.
bioRxiv · Dec 24, 2023 · PreprintImmunology
C. Qian, Q. Yang, M. Rotinen, R. Huang, h. Kim, B. Gallent, Y. Yan, R. M. Cadaneanu, B. Zhang, S. Kaochar, S. J. Freedland, E. M. Posadas, L. Ellis, D. Di Vizio, C. Morrissey, , M. R. Freeman
This study identifies ONECUT2 as a master transcription factor that drives resistance in prostate cancer through multiple mechanisms, including activation of neuroendocrine and adenocarcinoma variants, and shows that its inhibition can suppress treatment-resistant lineage plasticity.
bioRxiv · Sep 28, 2023 · PreprintCancer Biology
E. Bose, C. Mayes, L. Ellis, C. Baker, S. Tambalotti, B. Eusse, S. Xiong, Y. P. O. Sarpong, M. Shalaby, L. Barry, F. Lewis, J. Joseph, T. Isaacs, D. McCarthy, D. Katz, , A. Jones
This study characterizes RBM15's RNA binding mechanism through bioinformatics and experiments, showing it interacts with stem-loop RNA motifs via RRMs 2 and 3.
bioRxiv · Jul 20, 2023Biochemistry
K. L. Morel, A. A. Hamid, B. G. Falcon, J. N. Singh, S. Linder, A. M. Bergman, H. G. van der Poel, I. Hofland, E. M. Bekers, S. Trostel, S. Wilkinson, A. T. Ku, D. L. Burkhart, M. Kim, J. Kim, , L. Ellis
This study shows that loss of ZFP36 promotes NF-κB activation and phenotypic plasticity in prostate cancer, leading to aggressive disease and castration resistance, which can be reversed by NF-κB inhibition.
bioRxiv · Aug 5, 2022 · PreprintCancer Biology
M. Rathore, M. Wright, R. Bhattacharya, F. Fan, A. Vaziri-Gohar, J. Winter, Z. Wang, S. Markowitz, J. Willis, L. Ellis, R. Wang
The paper shows liver endothelial cells promote HER3-mediated survival in KRAS wild-type and mutant colorectal cancer cells through secreted factors, suggesting HER3 as a therapeutic target regardless of KRAS mutation status.
bioRxiv · Apr 27, 2021 · PreprintCancer Biology
S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman
The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.
bioRxiv · Oct 23, 2020Cancer Biology
P. Cejas, Y. Xie, A. Font-Tello, K. Lim, S. Symala, X. Qiu, A. Tewari, N. Shah, H. Nguyen, R. Patel, L. Brown, I. Coleman, W. M. Hackeng, L. Brosens, K. Dreijerink, , H. W. Long
This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.
bioRxiv · Sep 13, 2020Cancer Biology
Z. Bakouny, D. A. Braun, S. A. Shukla, W. Pan, X. Gao, Y. Hou, A. Flaifel, S. Tang, A. Bosma-Moody, M. X. He, N. Vokes, J. Nyman, W. Xie, A. H. Nassar, S. Abou Alaiwi, , T. H. Ho
This study characterizes the molecular features and immune profile of sarcomatoid and rhabdoid renal cell carcinoma, showing their responsiveness to immune checkpoint inhibitors and identifying key genetic and transcriptional determinants.
bioRxiv · May 28, 2020Cancer Biology
A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis
This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.
bioRxiv · Aug 8, 2019 · PreprintCancer Biology
H. VanDeusen, J. R. Ramroop, K. L. Morel, A. V. Sheahan, Z. Sychev, N. A. Lau, L. C. Cheng, V. Tan, Z. Li, A. Petersen, J. K. Lee, J. Wook Park, R. Yang, I. Coleman, O. N. Witte, , J. M. Drake
The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.
bioRxiv · Apr 29, 2019Cancer Biology